Skip to main content

Advertisement

Table 5 Characteristics and outcomes of patients treated for hepatitis C in the HIV primary care model dichotomized according to risk category based on assigned HCV treatment monitoring group*

From: Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model

Clinic model High-risk Non-high-risk P value
  (n = 17) (n = 31)  
Median age - years (range) 49 (19–61) 47 ( 33–61) 0.77a
Sex: Male (%) 14 (82) 24 (77) 0.68b
Race    
White 13 19 0.14c
Black 2 11
Other/unknown 2 1
Ethnicity    
Hispanic 2 5 0.68c
Not-Hispanic 15 26
Median T CD4+ cell count - cells/mm3 (range) 515(130–1136) 529(170–1140) 0.55a
Number with undetectable HIV load (%) 14 (82) 26 (84) 0.91b
Hepatitis C genotype    
Genotype 1/4 13 26 0.53b
Genotype 2/3 4 5
Median HCV load - log10 copies/mL (range) 6.44(4.05–7.46) 6.40(3.0–7.6) 0.73a
Liver biopsy scores 1    
F0-2 4 8 0.51c
F3,4 6 7
Median Hemoglobin levels - g/dL (range) 14.5(12.9–15.8) 14.4(12.1–16.6) 0.63a
Median Platelet count -1000/mm3 (range) 191(113–418) 227(119–402) 0.38a
Median ALT - U/L (range) 85(22–301) 56(19–1087) 0.08a
HCV treatment outcomes    
№ Patients with Sustained viral response (%) 5(29) 16(52) 0.14b
№ Patients who discontinued HCV therapy due to non-viral response (%) 2(12) 7(23) 0.36b
№ Patients who discontinued HCV therapy due to treatment-related side effects (%) 6(35) 8(26) 0.49b
№ Patients lost to follow-up (%) 3(18) 1(3) 0.08b
  1. * High-risk patients comprised patients with substance use and/or homelessness (n = 10) and severe psychiatry and/or medical comorbidities (n = 7).
  2. 1 Liver biopsies were not performed in 6 patients with genotype 1 in the high-risk (n = 3) and non-high risk (n = 3) respectively.
  3. a Wilcoxon Rank-Sum Test.
  4. b Chi-square test.
  5. c Fisher’s exact test.